{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:24:26Z","timestamp":1775550266014,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis It is a Novartis Sponsored Study","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril\/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II\u2013IV, and left ventricular ejection fraction (LVEF) \u226440%. Participants were randomized 1:1 to sacubitril\/valsartan (97\/103\u2009mg bid) or enalapril (10\u2009mg bid). Enrolled participants (mean age: 64.2\u2009years, 42.0% women) had a baseline LVEF of 29.8% (NYHA class II: 61.7%; NHYA class III\/IV: 38.2%). History included hypertension (40.5%), atrial fibrillation\/flutter (32.5%), ventricular arrhythmia (24.7%) and stroke (12.5%). The majority of patients had cardiac conduction abnormalities and 46.0% had conventional pacemaker, cardiac resynchronization therapy or implantable cardioverter-defibrillator. Mean systolic blood pressure was 118\u2009mmHg, and median NT-proBNP level was 1730\u2009pg\/ml.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline characteristics of this study highlight the unique clinical profile of patients with CCC-related HFrEF, including the high proportion of women affected, lower rates of comorbidities (hypertension\/diabetes) and higher prevalence of stroke and pacemaker implantation when compared with other non-CCC-related HFrEF studies. These findings reinforce the need for dedicated heart failure treatments in this neglected subpopulation, particularly in Latin America where Chagas disease remains a significant public health issue.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.70026","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T08:05:02Z","timestamp":1757318702000},"page":"2879-2886","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sacubitril\/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy with Heart Failure: Baseline Characteristics of the PARACHUTE-HF Trial"],"prefix":"10.1093","volume":"27","author":[{"given":"Luis Eduardo","family":"Echeverria","sequence":"first","affiliation":[{"name":"Fundaci\u00f3n Cardiovascular de Colombia, Universidad de Santander , Floridablanca ,","place":["Colombia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edimar","family":"Bocchi","sequence":"additional","affiliation":[{"name":"Heart Failure Clinics, Instituto do Cora\u00e7\u00e3o (InCor), Hospital das Clinicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5823-1135","authenticated-orcid":false,"given":"Caroline","family":"Demacq","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Gabriel Melo","family":"de Barros e Silva","sequence":"additional","affiliation":[{"name":"Brazilian Clinical Research Institute (BCRI) , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu-May","family":"Chiang","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarfaraz","family":"Sayyed","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Petri","family":"Damiani","sequence":"additional","affiliation":[{"name":"Brazilian Clinical Research Institute (BCRI) , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian Mazza","family":"Barbosa","sequence":"additional","affiliation":[{"name":"Brazilian Clinical Research Institute (BCRI) , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remo Holanda de Mendon\u00e7a","family":"Furtado","sequence":"additional","affiliation":[{"name":"Brazilian Clinical Research Institute (BCRI) , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Morillo","sequence":"additional","affiliation":[{"name":"Libin Cardiovascular Institute, University of Calgary , Calgary, AB ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Kevorkian","sequence":"additional","affiliation":[{"name":"Hospial D.F. Santojanni, Buenos Aires University , Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Ramires","sequence":"additional","affiliation":[{"name":"Heart Failure Clinics, Instituto do Cora\u00e7\u00e3o (InCor), Hospital das Clinicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cecilia","family":"Bahit","sequence":"additional","affiliation":[{"name":"INECO Neurociencias Oro\u00f1o , Rosario ,","place":["Argentina"]},{"name":"Baim Institute for Clinical Research , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"Chavez-Mendoza","sequence":"additional","affiliation":[{"name":"Hospital de Cardiologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social , Mexico City ,","place":["Mexico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Maga\u00f1a-Serrano","sequence":"additional","affiliation":[{"name":"Hospital de Cardiologia, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social , Mexico City ,","place":["Mexico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justo","family":"Carbajales","sequence":"additional","affiliation":[{"name":"Hospital Ramos Mejia , Buenos Aires ,","place":["Argentina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson","family":"Oliveira Junior","sequence":"additional","affiliation":[{"name":"Pronto-Socorro Cardiol\u00f3gico da Universidade de Pernambuco , Recife ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Molina","sequence":"additional","affiliation":[{"name":"Postgraduate Program in Health Sciences, State University of Montes Claros , Montes Claros ,","place":["Brazil"]},{"name":"Department of Infectious Diseases, Vall d'Hebron University Hospital, PROSICS Barcelona; Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aguinaldo F.","family":"Freitas Junior","sequence":"additional","affiliation":[{"name":"Universidade Federal de Goi\u00e1s , Goiania ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria da Consola\u00e7ao","family":"Moreira","sequence":"additional","affiliation":[{"name":"Felicio Rocho Hospital , Belo Horizonte ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adegil Henrique","family":"Silva","sequence":"additional","affiliation":[{"name":"Instituto de Cardiologia e Transplantes do Distrito Federal do Distrito Federal , Brasilia ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Telemaco","family":"Silva Junior","sequence":"additional","affiliation":[{"name":"Eurolatino Pesquisas Medicas , Uberl\u00e2ndia ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wladimir","family":"Saporito","sequence":"additional","affiliation":[{"name":"Pesquisare Saude , Santo Andr\u00e9 ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Francisco","family":"Kerr Saraiva","sequence":"additional","affiliation":[{"name":"Clinical Research Institute of Campinas , Campinas ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Gimpelewicz","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-4961","authenticated-orcid":false,"given":"Renato Delascio","family":"Lopes","sequence":"additional","affiliation":[{"name":"Brazilian Clinical Research Institute (BCRI) , S\u00e3o Paulo ,","place":["Brazil"]},{"name":"Duke University School of Medicine , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"2026021721513372500_ejhf70026-bib-0001","volume-title":"Global, Regional, and National Burden of Chagas Disease, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study 2023 (June 18, 2025)","author":"Cousin"},{"key":"2026021721513372500_ejhf70026-bib-0002","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jacc.2017.08.004","article-title":"Chronic Chagas heart disease management: From etiology to cardiomyopathy treatment","volume":"70","author":"Bocchi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026021721513372500_ejhf70026-bib-0003","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.puhe.2023.11.034","article-title":"Chagas disease deaths detected among garbage codes registered in mortality statistics in Brazil: A study from the buRden of ChAgas dISEase in the contemporary world (RAISE) project","volume":"227","author":"Franca","year":"2024","journal-title":"Public Health"},{"key":"2026021721513372500_ejhf70026-bib-0004","article-title":"Prevalence of clinical forms of Chagas disease: A systematic review and meta-analysis \u2013 data from the RAISE study","volume":"30","author":"Nascimento","year":"2024","journal-title":"Lancet Reg Health Am"},{"key":"2026021721513372500_ejhf70026-bib-0005","first-page":"31","article-title":"Chagas cardiomyopathy: Clinical presentation and management in the Americas","volume":"35","author":"Benziger","year":"2017","journal-title":"Cardiol Clin"},{"key":"2026021721513372500_ejhf70026-bib-0006","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1002\/ejhf.3460","article-title":"Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three-headed monster","volume":"26","author":"Echeverria","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021721513372500_ejhf70026-bib-0007","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004361","article-title":"Contemporary characteristics and outcomes in Chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy","volume":"10","author":"Shen","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026021721513372500_ejhf70026-bib-0008","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1161\/CIR.0000000000000599","article-title":"Chagas cardiomyopathy: An update of current clinical knowledge and management: A scientific statement from the American Heart Association","volume":"138","author":"Nunes","year":"2018","journal-title":"Circulation"},{"key":"2026021721513372500_ejhf70026-bib-0009","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijcard.2012.01.033","article-title":"Outcome of Chagas cardiomyopathy in comparison to ischemic cardiomyopathy","volume":"167","author":"Vilas Boas","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026021721513372500_ejhf70026-bib-0010","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0140-6736(20)30171-9","article-title":"Chagas disease: Still a neglected emergency?","volume":"395","author":"Lopes","year":"2020","journal-title":"Lancet"},{"key":"2026021721513372500_ejhf70026-bib-0011","article-title":"SBC guideline on the diagnosis and treatment of patients with cardiomyopathy of Chagas disease \u2013 2023","volume":"120","author":"Marin-Neto","year":"2023","journal-title":"Arq Bras Cardiol"},{"key":"2026021721513372500_ejhf70026-bib-0012","first-page":"436","article-title":"Diretriz Brasileira de Insufici\u00eancia Card\u00edaca Cr\u00f4nica e Aguda","volume":"111","author":"Rohde","year":"2018","journal-title":"Arq Bras Cardiol"},{"key":"2026021721513372500_ejhf70026-bib-0013","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021721513372500_ejhf70026-bib-0014","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/ehf2.12355","article-title":"Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy. Comment on: \u201cSafety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: A post hoc analysis of the SHIFT trial\u201d by Bocchi et al","volume":"5","author":"Ramires","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026021721513372500_ejhf70026-bib-0015","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jchf.2024.05.021","article-title":"Sacubitril\/valsartan versus enalapril in chronic Chagas cardiomyopathy: Rationale and design of the PARACHUTE-HF trial","volume":"12","author":"Bocchi","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026021721513372500_ejhf70026-bib-0016","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/08037059209077502","article-title":"Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective randomized open blinded end-point","volume":"1","author":"Hansson","year":"1992","journal-title":"Blood Press"},{"key":"2026021721513372500_ejhf70026-bib-0017","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ejhf.115","article-title":"Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)","volume":"16","author":"McMurray","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026021721513372500_ejhf70026-bib-0018","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ejhf.408","article-title":"The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): Revised statistical analysis plan and baseline characteristics","volume":"17","author":"Krum","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026021721513372500_ejhf70026-bib-0019","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: Baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021721513372500_ejhf70026-bib-0020","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021721513372500_ejhf70026-bib-0021","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/ejhf.2015","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials","volume":"22","author":"Teerlink","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021721513372500_ejhf70026-bib-0022","doi-asserted-by":"crossref","DOI":"10.36660\/abc.20240555i","article-title":"Acute heart failure in patients with Chagas cardiomyopathy: Results of the I Brazilian Heart Failure Registry (BREATHE)","volume":"122","author":"Silva","year":"2025","journal-title":"Arq Bras Cardiol"},{"key":"2026021721513372500_ejhf70026-bib-0023","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.58","article-title":"Heart failure with reduced ejection fraction","volume":"3","author":"Bloom","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2026021721513372500_ejhf70026-bib-0024","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","article-title":"Randomized trial of benznidazole for chronic Chagas' cardiomyopathy","volume":"373","author":"Morillo","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021721513372500_ejhf70026-bib-0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.thromres.2021.02.025","article-title":"Coagulation disorders in Chagas disease: A pathophysiological systematic review and meta-analysis","volume":"201","author":"Echeverria","year":"2021","journal-title":"Thromb Res"},{"key":"2026021721513372500_ejhf70026-bib-0026","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ejhf.1972","article-title":"Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF and ATMOSPHERE","volume":"22","author":"Kristensen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021721513372500_ejhf70026-bib-0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006567","article-title":"Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis","volume":"12","author":"Rojas","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2026021721513372500_ejhf70026-bib-0028","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01787-7","article-title":"Chagas disease","volume":"403","author":"Sousa","year":"2024","journal-title":"Lancet"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/12\/2879\/66836244\/eurjhf_27_12_2879.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/12\/2879\/66836244\/eurjhf_27_12_2879.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:51:40Z","timestamp":1771383100000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/12\/2879\/8470657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,8]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.70026","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"2025-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}